ORTHOCELL LIMITED — AGM Information 2023

Sep 3, 2023

==> picture [594 x 145] intentionally omitted <==

Date of AGM & Closing Date for Director Nominations

Perth, Australia; 4 September 2023: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) advises, in accordance with ASX Listing Rule 3.13.1, that the 2023 Annual General Meeting (“AGM”) of the Company will be held on Tuesday, 31 October 2023.

An item of business at the AGM will be the re-election of Directors. The Company advises that, in accordance with clause 6.1 of the Company’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is Monday, 11 September 2023.

Any nominations must be received at the Company’s registered office no later than 5.00 pm WST on Monday, 11 September 2023.

Release authorised by:

Paul Anderson Managing Director Orthocell Ltd.

For more information, please contact:

General & Investor enquiries Media enquiries Paul Anderson Haley Chartres Orthocell Limited H^CK Director Managing Director P: +61 8 9360 2888 P: +61 423 139 163 E: paul.anderson@orthocell.com.au E: haley@hck.digital

About Orthocell Limited

ACN 118 879 135 Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer, manufacturing scale up and FDA engagement in advance of a randomised controlled study under FDA supervision.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @Orthocellltd and LinkedIn www.linkedin.com/company/orthocell-ltd

==> picture [43 x 28] intentionally omitted <==

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au